Trends in Disease Burden of Chronic Myeloid Leukemia at the Global, Regional, and National Levels: a Population-based Epidemiologic Study

Overview

Journal Exp Hematol Oncol

Publisher Biomed Central

Specialty Hematology

Date 2020 Dec 9

PMID 33292593

Citations 16

Authors

Liqing Ning

Chuanyu Hu

Pingfan Lu

Yimei Que

Xiaojian Zhu

Dengju Li

Affiliations

Soon will be listed here.

Abstract

Background: Outcomes of chronic myeloid leukemia (CML) has been improved dramatically in the past two decades, but survival levels of CML patients varied in regions. Comprehensive epidemiological research is necessary to evaluate the global burden of CML.

Methods: All data used in our study came from the Global Burden of Disease (GBD) study 2017. Incidence cases, death cases, disability-adjusted life-years (DALYs), and its corresponding age-standardized rate between 1990 to 2017 were used to describe the distribution of CML burden, according to age, sex, social-demographic index (SDI), and countries. Data about attributable risk factors contributing to CML deaths and DALYs were also extracted and analyzed.

Results: Globally, the disease burden of CML gradually decreased from 1990 to 2017. Higher SDI countries achieved a remarkable effect on diminishing the CML burden. Conversely, due to population growth, the incidence cases, death cases, and DALYs of CML in lower SDI quintiles showed an upward trend. India had the most incidence cases and death cases of CML in the world. Additionally, smoking was the most significant attributable risk factor contributing to CML deaths and DALYs, followed by high body mass index.

Conclusion: The disease burden of CML decreased globally, especially in higher SDI countries in the past 28 years. The increasing incidence cases and death cases were mainly observed in lower SDI countries. Additionally, strategies to control modifiable risk factors such as smoking and high body mass index might be useful in diminishing mortality and DALYs.

Citing Articles

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa.

Woudberg R, Sinanovic E Front Pharmacol. 2025; 15():1511603.

PMID: 39840079 PMC: 11746066. DOI: 10.3389/fphar.2024.1511603.

An Ultra-Fast Validated Green UPLC-MS/MS Approach for Assessing Revumenib in Human Liver Microsomes: In Vitro Absorption, Distribution, Metabolism, and Excretion and Metabolic Stability Evaluation.

Attwa M, Abdelhameed A, Kadi A Medicina (Kaunas). 2025; 60(12.

PMID: 39768795 PMC: 11679331. DOI: 10.3390/medicina60121914.

Comparison of secular trends of leukemia in China and the United States from 1990 to 2021 and their projections for the next 15 years.

Ge X, Zhang L, Zhang Q, Feng J, Yang L, Tong Y Front Public Health. 2024; 12:1425043.

PMID: 39220457 PMC: 11363266. DOI: 10.3389/fpubh.2024.1425043.

Global Trial Representation and Availability of Tyrosine Kinase Inhibitors for Treatment of Chronic Myeloid Leukemia.

Casey M, Odhiambo L, Aggarwal N, Shoukier M, Islam K, Cortes J Cancers (Basel). 2024; 16(16).

PMID: 39199609 PMC: 11352545. DOI: 10.3390/cancers16162838.

Temporal trends of migraine and tension-type headache burden across the BRICS: implications from the Global Burden of Disease study 2019.

Zhang Y, Li X, Guo Z Front Neurol. 2024; 14:1307413.

PMID: 38187142 PMC: 10771321. DOI: 10.3389/fneur.2023.1307413.

References

Jha P, Peto R . Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med. 2014; 370(1):60-8. DOI: 10.1056/NEJMra1308383. View

Campiotti L, Suter M, Guasti L, Piazza R, Gambacorti-Passerini C, Grandi A . Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. Eur J Cancer. 2017; 77:48-56. DOI: 10.1016/j.ejca.2017.02.028. View

Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet. 2007; 370(9584):342-50. DOI: 10.1016/S0140-6736(07)61165-9. View

Gomez-Almaguer D, Cantu-Rodriguez O, Gutierrez-Aguirre C, Ruiz-Arguelles G . The treatment of CML at an environment with limited resources. Hematology. 2016; 21(10):576-582. DOI: 10.1080/10245332.2016.1182695. View

Castillo J, Reagan J, Ingham R, Furman M, Dalia S, Merhi B . Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012; 36(7):868-75. DOI: 10.1016/j.leukres.2011.12.020. View

Malhotra H, Radich J, Garcia-Gonzalez P . Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):433-442. PMC: 6913442. DOI: 10.1182/hematology.2019000050. View

Gomez-De-Leon A, Gomez-Almaguer D, Ruiz-Delgado G, Ruiz-Arguelles G . Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. Expert Rev Hematol. 2017; 10(9):809-819. DOI: 10.1080/17474086.2017.1360180. View

Lee S . Chronic myelogenous leukaemia. Br J Haematol. 2001; 111(4):993-1009. DOI: 10.1046/j.1365-2141.2000.02216.x. View

Barnes D, Melo J . Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol. 2002; 108(4):180-202. DOI: 10.1159/000065655. View

10.

Hochhaus A, Baccarani M, Silver R, Schiffer C, Apperley J, Cervantes F . European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984. PMC: 7214240. DOI: 10.1038/s41375-020-0776-2. View

11.

Bilano V, Gilmour S, Moffiet T, Tursan dEspaignet E, Stevens G, Commar A . Global trends and projections for tobacco use, 1990-2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control. Lancet. 2015; 385(9972):966-76. DOI: 10.1016/S0140-6736(15)60264-1. View

12.

Islami F, Torre L, Drope J, Ward E, Jemal A . Global Cancer in Women: Cancer Control Priorities. Cancer Epidemiol Biomarkers Prev. 2017; 26(4):458-470. DOI: 10.1158/1055-9965.EPI-16-0871. View

13.

Verovskaya E, Dellorusso P, Passegue E . Losing Sense of Self and Surroundings: Hematopoietic Stem Cell Aging and Leukemic Transformation. Trends Mol Med. 2019; 25(6):494-515. PMC: 7657013. DOI: 10.1016/j.molmed.2019.04.006. View

14.

Chooi Y, Ding C, Magkos F . The epidemiology of obesity. Metabolism. 2018; 92:6-10. DOI: 10.1016/j.metabol.2018.09.005. View

15.

Cortes J, Rea D, Lipton J . Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2018; 94(3):346-357. PMC: 6587857. DOI: 10.1002/ajh.25342. View

16.

Rokholm B, Baker J, Sorensen T . The levelling off of the obesity epidemic since the year 1999--a review of evidence and perspectives. Obes Rev. 2010; 11(12):835-46. DOI: 10.1111/j.1467-789X.2010.00810.x. View

17.

Popkin B, Adair L, Ng S . Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012; 70(1):3-21. PMC: 3257829. DOI: 10.1111/j.1753-4887.2011.00456.x. View

18.

Mendizabal A, Younes N, Levine P . Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia. Int J Hematol. 2015; 103(1):70-8. DOI: 10.1007/s12185-015-1893-y. View

19.

Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K . The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020; 13(1):72. PMC: 7282046. DOI: 10.1186/s13045-020-00908-z. View

20.

Delord M, Foulon S, Cayuela J, Rousselot P, Bonastre J . The rising prevalence of chronic myeloid leukemia in France. Leuk Res. 2018; 69:94-99. DOI: 10.1016/j.leukres.2018.04.008. View